Carpmaels & Ransford LLP

Methods and systems of mapping electrophysiological signals in a heart using a catheter having an ultra-high density electrode array are disclosed. The disclosed technology can include a method including navigating a medical probe to a target location in a patient's heart; receiving electrophysiological signals from at least some of the electrodes of the plurality of electrodes; identifying, based on the electrophysiological signals and the location signal, an earliest activation point identified as having the earliest activation time; identifying, based on the electrophysiological signals and the location signal, a plurality of points closest to the earliest activation point having an activation time less than a predetermined time duration from the earliest activation time; and generating an electro-anatomical map of the heart based on data corresponding to the plurality of points, the electro-anatomical map representing the location of the earliest activation point for subsequent ablation.

The invention relates to a method of covalently attaching cationic polymers, including poly(beta-amino esters), to magnetic nanoparticles. The invention further relates to magnetic nanoparticles comprising cationic polymers covalently attached thereto, polyplexes comprising the magnetic nanoparticles, as well as use of these nanoparticles and polyplexes in delivering nucleic acids to a target tissue.

A system includes a catheter, an electrocardiogram (ECG) system, and a processor. The catheter is configured to apply pacing to given tissue location inside a ventricle of heart of patient. The ECG system is configured to acquire a set of ECG signals generated in response to the pacing, wherein electrodes of the ECG system attached to the patient define respective directions in space relative to an origin located in the heart. The processor is configured to (i) calculate respective set of signal differences between the acquired set of ECG signals and reference set of ECG signals, (ii) calculate corresponding set of deviation vectors along the respective directions in space, the deviation vectors having amplitudes corresponding to the respective signal differences, (iii) using the deviation vectors, calculate direction vector from the given location to new ventricle location at which to apply the pacing, and (iv) indicate calculated direction vector to user.

Methods may include receiving, at a computing device, at least one coordinate set associated with a catheter tip. Methods may include receiving, at the computing device, at least one three-dimensional (3D) model of a heart. Methods may include determining, based on at least the at least one 3D model, an endocardial surface of the heart. Methods may include determining, based on at least the at least one 3D model, an epicardial surface of the heart. Methods may include causing a vector to be projected from the catheter tip. The vector may intersect the endocardial surface at a first point. The vector may intersect the epicardial surface at a second point. Methods may include determining, using at least the first point and the second point, a tissue thickness. Methods may include causing, via a display, output of an indication of the tissue thickness.

A catheter is presented having a planar end effector with elongated ablation electrodes configured to provide electrical signals to achieve IRE in target tissue. The planar end effector can be aligned along a longitudinal axis of a shaft of the catheter and configured to flex away from the longitudinal axis when making contact with tissue. Bipolar electrical signals can be applied between the elongated ablation electrodes in various pair combinations to achieve PFA. The end effector may also include diagnostic electrodes configured to receive electrical signals from tissue to map tissue, pairs of tissue contact electrodes to determine which portions of the end effector are in contact with tissue, or reference electrodes configured to measure blood voltage.

The present invention relates to organoid co-cultures and their use in the investigation of diseases. The co-culture comprises at least one organoid, at least one stromal cell, and at least one immune cell. The presence or absence of the at least one change in the co-culture is determined e.g. in response to a proinflammatory stimulus.

Described herein are systems and methods for analyzing biological samples. Including a method for processing an analyte, comprising providing a fluidic device comprising the analyte and one or more polymer precursors; selecting a discrete area within said fluidic device; providing an energy source in optical communication with fluidic device; and selectively supplying a unit of energy generated from the energy source to the fluidic device to generate a polymer matrix within the fluidic device, wherein the polymer matrix is within the discrete area or adjacent to the discrete area.

Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a large B cell lymphoma, such as a diffuse large B-cell lymphoma (DLBCL). Also provided are methods of assessing the risk of developing a toxicity related to a cell therapy, and methods of identifying subjects and methods of treating subjects based on the assessment of risks.

The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.

Methods and systems for genetic and epigenetic profiling of DNA samples and detecting genetic and epigenetic changes in DNA samples are provided, which involve digestion of DNA with methylation-sensitive restriction enzymes, followed by high-throughput sequencing and analysis of sequence reads. Advantageously, the methods and systems of the present invention are sensitive yet accurate, and enable working with very low amounts of DNA and receive vast amount of information, including methylation data, mutation data and more, based on sequencing data from a single run.